RxDoctor Payments Data

Lisa Wirth, MD

Psychiatry · Gainesville, GANPI 1932171758

Payments from drug & device makers

$6,542in general payments, 2019–2025

Across 454 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$1K
  • Alkermes, Inc.$684
  • Vanda Pharmaceuticals Inc.$351
  • Takeda Pharmaceuticals U.S.A., Inc.$297
  • Sunovion Pharmaceuticals Inc.$293
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,42498%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,542 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$47,167
Medicare patients
229
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine27$189,124
VraylarCariprazine Hcl76$108,879
TrintellixVortioxetine Hydrobromide89$50,404
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine787$22,797
Aripiprazole330$18,104
Vilazodone Hcl111$11,657
VyvanseLisdexamfetamine Dimesylate26$9,914
Duloxetine Hcl617$8,644
Lamotrigine833$7,346
Alprazolam1,299$7,017
Venlafaxine Hcl ErVenlafaxine Hcl498$6,649
CymbaltaDuloxetine Hcl12$6,621
Trazodone Hcl659$6,378
Clonazepam910$6,308
Divalproex Sodium ErDivalproex Sodium109$5,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$180$189,12427 claims
AbbVieVraylar$1,187$108,87976 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$297$60,318115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →